Histone deacetylase 3 expression correlates with vasculogenic mimicry through the phosphoinositide 3-kinase/ERK--MMP--laminin5γ2 signaling pathway
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Vasculogenic mimicry refers to the process by which tumor cells mimic endothelial cells to form vessel-like structures that aid in supplying nutrients to rapidly growing tumors. However, the pathway by which this occurs is not fully delineated. In this study, Liu et al. focused on histone deacetylase 3 (HDAC3), a certain histone deacetylase known to be overexpressed in carcinomas. They studied human glioma cells *in vitro* and, using immunohistochemical staining, showed that HDAC3 expression positively correlates not only with the formation of these vessel-like structures, but also the grade of the pathology. Furthermore, they observed, through addition of inhibitors, that HDAC3 is likely working on the phosphoinositide 3-kinase/ERK--MMPs--laminin5γ2 signaling pathway, thus providing a possible future target for therapeutic approaches.doi: [10.1111/cas.12684](10.1111/cas.12684)

Non-steady-state hematopoiesis regulated by the C/EBPβ transcription factor
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In this review article, Hirai and colleagues explore what is known about the CCAAT/enhancer-binding protein β (C/EBPβ) transcription factor and its pathway as it relates to chronic forms of leukemia. Specifically, they discuss the role of C/EBPβ in granulopoiesis and myelopoeisis in infection and cancer; C/EBPβ is the driver of non-steady-state conditions in a healthy cell, but becomes hijacked in cancer cells. In this review article, the important role of C/EBPβ -- although still not completely understood -- is given credit it duly deserves as a key player in leukemias.doi: [10.1111/cas.12690](10.1111/cas.12690)

*EVI1*, a target gene for amplification at 3q26, antagonizes transforming growth factor-β-mediated growth inhibition in hepatocellular carcinoma
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Hepatocellular carcinoma (HCC) is an aggressive malignancy that has few effective chemotherapies or targeted agents, which has motivated researchers to better understand the molecular pathways underlying HCC proliferation. Yasui and colleagues present their work in this issue of *Cancer Science*, where they look to another aggressive cancer, myeloid leukemia, for a target that may also be involved in HCC. The authors identified *EVI1* as an oncogene involved in myeloid leukemia, but through a series of cell culture experiments, they found that it also plays an important role in the progression of HCC.

Specifically, Yasui and coworkers found that high EVI1 expression was associated with cell signaling cascades that are classically tumorigenic, and that knockdown of the *EVI1* gene led to reduced HCC cell viability. These exciting findings suggest that *EVI1* may be an important new target for future systemic therapies.doi:[10.1111/cas.12694](10.1111/cas.12694)
